|
Workshop
Good Manufacturing Practices (GMPs) from R&D through Commercialization: Fundamentals, Regulatory Trends and Best Practices
Speakers:
Marion Weinreb, President, MWA Consulting, Inc.
Organizers:
Date:
2017-10-24
Time:
13:00-17:30 Pacific Time
Registration fee:
(USD): Regular: $125; Academic: $75; For unemployed or students: $25; For vendor-show reps: $25; For major-sponsor rep (incl lunch): $0
Location:
SF Bay Area: Foster City Crowne Plaza
Major Sponsor:
Vendor show vendors registered to date:
(7)BioDuro; BioKey, Inc.; Lonza; MabPlex; MilliporeSigma; Nitto Avecia Pharma Services, Inc.; PerkinElmer
Registration: http://www.PBSS.org
Registration deadline:2017-10-23
(it will close sooner if the seating cap is reached)
About the Topic
This workshop will include a discussion on the history of Good Manufacturing Practices (GMP) regulations from R&D through Commercialization, the importance of the regulations, key definitions, areas covered by the GMPs, a review of the regulations, examples of misconduct and, potential FDA actions. After completing this workshop, participants should be able to understand the origin, purpose, and expectations of the GMP regulations.
12:45-12:55 pm
- PBSS Welcome & Workshop Overview
- History of Drug Regulations
- Basis of GMPs
12:55-2:00 pm
- CGMPs on a Continuum
- Development vs Commercial Compliance
- Review of Clinical Failures and Commercial Recalls
2:00-2:10 pm
- Major Sponsor Presentation
2:10-2:25 pm
2:25-3:40 pm
- Current FDA Expectations and Focus
- Data Integrity
- Quality Metrics
- Quality by Design
3:40-4:00 pm
4:00-5:00 pm
5:00-5:20pm
About the SpeakersMarion Weinreb has over 40 years of quality systems experience in the medical device and pharmaceutical industries. Marion has worked at major companies like Altana, Inc., Forest Laboratories, Johnson & Johnson, Syntex and Roche Bioscience. She focuses on GMP and/or QSR auditing in both non-sterile and sterile drug, device and combination systems, Pre-Approval Inspection preparation, PAI mock audits, quality systems development and continuous improvement, cGXP training, GMP document development, and problem resolution for compliance issues. She has worked for small and large companies and has a successful track record for dealing with complex compliance issues in development and commercial settings. Marion holds a BA in Biology and an MS in Pharmaceutical Marketing. She is currently President of MWA Consulting, Inc. where provides GXP consulting expertise to MWA clients.
2024-04-12, [Free Online] Innovative Life Science Technologies in the Drug Development Toolbox: From Cancer Organoids and Biomarker Profiling to Label-Free Multiplex QES Assays
|
2024-04-26, [In-Person] Oncology Clinical Dose Optimization in Light of FDA Project Optimus
|
2024-05-06, [In-Person] Human Mass Balance and Metabolite Profiling Studies: Strategies, Technical Approaches, Regulatory Guidance, Applications and Case Studies
|
2024-05-13, [Free Online] Highlights of 2023 FDA Drug Approvals
|
2024-05-21, [In-Person] Nonclinical Safety Studies for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
|
2024-05-30, [Online Workshop] Career Transition for Research Scientists
|
2024-06-13, [In-Person] CMC Strategies and Activities for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
|
2024-06-20, Alzheimer's Disease: untangling what we thought we knew and future Precision Medicine Diagnostics and Therapeutics
|
2024-09-10, [In-Person] Rethinking Translational PK/PD and Human Dose Projections for Novel Therapeutic Modalities: Covalent Inhibitors, PROTACs, Molecular Glues, ADCs, Ocular and Neuro delivery, Vaccines, Bispecifics, Cell and Gene Therapies
|
2024-09-20, [In-Person] Non-clinical safety assessments of biologics and novel modalities for IND/NDA Filing: Nuts, Bolts and Best Practices
|
2024-10-10, [In-Person] Regulatory Global Submission: Strategies and Best Practices for FDA, EMA and PMDA
|
|
Ads (in random order)
Submit a Text Ad ($250 for 2 months)
Lena Biosciences
Predictive toxicology. Mitochondrial toxicity in a drug metabolism-competent model with active transporters. Intrinsic & idiosyncratic DILI.
|
Alturas Analytics, Inc.
Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
|
Submit a Text Ad
|